STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after March 2003, please refer to module 8B 
• 
• 
• 
• 
• 
• 
• 
On  30  March  2000  the  MAH  (MAH)  submitted  to  the  EMEA  an  application  for  a  Type  I 
variation  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995,  as 
amended.  The  scope  of  this  variation  was  to  change  the  name  of  the  manufacturer  of  the 
finished  product  from  Circa  Pharmaceuticals  Inc.  to  Watson  Laboratories  Inc.  This  variation 
was  approved  by  the  EMEA  on  28  April  2000  and  did  not  require  any  amendments  to  the 
Commission Decision. 
On 30 March 2000 the MAH submitted to the EMEA an application for a Type II variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope  of this variation was to add an alternative active substance manufacturer Genzyme Ltd, 
Haverhill,  Suffolk,  UK  and  to  resubmit  the  originally  open  file  information  of  the  active 
substance  manufacturing  process  at  the  Dow  Chemical  Company  site  as  an  open/closed 
European Drug Master File (EDMF). The CPMP adopted a  positive opinion for this variation 
on  21  September  2000,  which  did  not  require  any  amendments  to  the  Community  Marketing 
Authorisation. 
On  30  March  2000,  the  MAH  submitted  an  application  for  a  marketing  authorisation  for 
Renagel film coated tablets, in accordance with Annex II to Commission Regulation (EC) No 
542/95  as  amended.  The  procedure  started  on  14  April  2000.  During  its  December  2000 
meeting,  the  CPMP, in light  of the  overall data  submitted and the scientific  discussion within 
the CPMP issued a positive opinion for granting a Marketing Authorisation for Renagel 400 mg 
film coated tablets and Renagel 800 mg film coated tablets on 14 December 2000. The CPMP 
opinion  was  forwarded  to  the  European  Commission,  which  adopted  the  corresponding 
Decision on 26 March 2001. 
On  10  January  2001,  the  MAH  applied  for  a  Type  I  variation  for  Renagel  hard  capsules,  in 
accordance  with  Commission  Regulation  (EC)  542/95  as  amended.  Additional  data  was 
submitted  on  1  February  2001.  The  MAH  applied  to  demonstrate  compliance  with  the 
Commission  Directive  1999/82/EC  and  the  Note  for  Guidance  on  Minimising  the  risk  of 
transmitting 
products 
encephalopathy 
(CPMP/BWP/1230/98),  and  provided  certificates  of  suitability  issued  by  the  European 
Pharmacopoeia. The EMEA considered this variation to be acceptable and issued on  2 March 
2001 a positive notification for the Type I variation application. 
via  medicinal 
spongiform 
animal 
agents 
On 20 February 2001, the MAH submitted an application for a Type II variation in accordance 
with  Article  6  of  European  Commission  Regulation  (EC)  542/95  as  amended.  The  MAH 
applied for an update of the section 4.8 of the SPC and PL to include flatulence based on the 1st 
PSUR. Some minor linguistic corrections were also applied for. The CPMP adopted a positive 
Opinion for this variation on 26 April 2001. The respective Commission Decision was issued on 
9 August 2001. 
On  14  May  2001  the  MAH  submitted  to  the  EMEA  an  application  for  a  Type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope of this variation was to add a new pack size of 100 tablets for the 800 mg strength. This 
variation was approved by the EMEA on 22 June 2001. The respective Commission Ddecision 
was issued on 15 October 2001. 
On 24 August 2001 the MAH submitted to the EMEA an application for a Type I variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope of this variation was a minor change in the manufacturing procedure. This variation was 
approved  by  the  EMEA  on  28  September  2001  and  did  not  require  any  amendments  to  the 
Community Marketing Authorisation. 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
On 30 October 2001 the MAH submitted to the EMEA an application for a Type I variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope of this variation was to change its name from Genzyme B.V. into Genzyme Europe B.V. 
This  variation  was  approved  by  the  EMEA  on  10  December  2001  and  did  not  require  any 
amendments to the Community Marketing Authorisation. 
On 30 October 2001 the MAH submitted to the EMEA an application for a Type I variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope of this variation was to upgrade the current seal for the 403 mg capsule bottle to provide 
better protection against moisture and to be of the same quality as the one used for Renagel 400 
mg/800  mg  film-coated  tablets.  This  variation  was  approved  by  the  EMEA  on  10  December 
2001 and did not require any amendments to the Community Marketing Authorisation. 
On  10  June  2002  the  MAH  submitted  to  the  EMEA  an  application  for  a  Type  I  variation  in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope  of  this  variation  was  a  change  of  the  manufacturing  site  for  part  or  all  of  the 
manufacturing process of the medicinal product. The procedure started on 27 June 2002. This 
variation was approved by the EMEA on 10 July 2002 and did not require any amendments to 
the Community Marketing Authorisation. 
On 3 September 2002 the MAH submitted to the EMEA an application for a Type I variation in 
accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The 
scope  of  this  variation  was  a  change  in  test  procedure  of  active  substance  and  the  medicinal 
product.  The  procedure  started  on  10  September  2002.  This  variation  was  approved  by  the 
EMEA  on  4  October  2002  and  did  not  require  any  amendment  to  the  Community  Marketing 
Authorisation. 
2/2 
EMEA 2005 
 
 
 
 
 
 
